“Cutaneous T-Cell Lymphoma Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cutaneous T-Cell Lymphoma Market.

The Cutaneous T-Cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cutaneous T-Cell Lymphoma treatment therapies with a considerable amount of success over the years.

• Cutaneous T-Cell Lymphoma companies working in the treatment market are Citius Pharmaceuticals, Soligenix, 4SC AG, Innate Pharma, Galderma R&D, Kyowa Kirin, Inc, oligenix, Ligand Pharmaceuticals, Bausch Health Americas, Inc., BioCryst Pharmaceuticals, Novartis, Celgene, Soligenix, Pfizer, Bioniz Therapeutics, Eisai Inc., Merck Sharp & Dohme LLC, and others, are developing therapies for the Cutaneous T-Cell Lymphoma treatment

• Emerging Cutaneous T-Cell Lymphoma therapies in the different phases of clinical trials are- I/ONTAK, HyBryte, Resminostat, Lacutamab, CD11301, Mogamulizumab, Hypericin, ONTAK (denileukin difitox, DAB389IL-2), Bexarotene, Forodesine 200 mg, Panobinostat, romidepsin (depsipeptide, FK228), SGX301 (synthetic hypericin), Ritlecitinib, BNZ132-1-40, ONTAK Pembrolizumab, and others are expected to have a significant impact on the Cutaneous T-Cell Lymphoma market in the coming years.

• In December 2025, Citius Oncology, Inc. (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), has announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor–targeted fusion protein that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) who have previously received at least one systemic therapy.

• In November 2025, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet needs, announced that it has successfully completed the planned enrollment of 50 patients for the interim analysis of its 80-patient, confirmatory Phase 3, double-blind, placebo-controlled trial assessing HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). The FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) confirmatory Phase 3 study expands on results from the earlier statistically significant Phase 3 FLASH trial, along with findings from a recent comparative study (HPN-CTCL-04) and a current investigator-initiated study.

• As estimated, the largest market size for Cutaneous T-cell Lymphoma (CTCL) is observed in the United States in 2022, and it is expected to expand at a Compound Annual Growth Rate (CAGR) of approximately 3%.

• In May 2025, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced the upcoming presentation of long-term follow-up results from the Phase 2 TELLOMAK study, which is assessing lacutamab an anti-KIR3DL2 monoclonal antibody in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two uncommon and aggressive subtypes of cutaneous T-cell lymphoma (CTCL). These findings will be shared at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois.

• In February 2025, Innate Pharma received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its lead candidate, lacutamab, for the treatment of adults with relapsed or refractory Sézary syndrome. Lacutamab is a pioneering antibody that specifically targets the killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2) to trigger cytotoxic activity. The therapy is currently under clinical investigation for its potential in treating cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma.

• In January 2025, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with unmet medical needs, has shared an interim update from an open-label, investigator-initiated study (IIS) evaluating prolonged use of HyBryte™ (synthetic hypericin) for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). The study is being led by Dr. Ellen Kim, Director of the Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations in the Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania. Dr. Kim also played a key role as a lead enroller in the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial investigating HyBryte™ in early-stage CTCL.

• In December 2024, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with high unmet needs, has announced the initiation of patient enrollment for its confirmatory Phase 3 clinical trial of HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). This new study, titled FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2), is designed to validate findings from the prior statistically significant Phase 3 FLASH trial. It is further supported by data from a recent successful comparative study (HPN-CTCL-04) and an ongoing investigator-initiated trial, reinforcing the trial’s foundation.

Cutaneous T-Cell Lymphoma Overview

Cutaneous T-Cell Lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that primarily affects the skin. It occurs when certain T-lymphocytes (a type of white blood cell) become cancerous and accumulate in the skin, leading to symptoms such as red patches, scaly plaques, itching, or tumor-like lesions.

The most common forms of CTCL include Mycosis Fungoides and Sézary Syndrome. The disease usually develops slowly and may remain limited to the skin for many years, but in advanced stages it can spread to the lymph nodes, blood, or internal organs.

Treatment options vary depending on the stage of the disease and may include topical therapies, phototherapy, radiation therapy, systemic medications, or immunotherapy. Early diagnosis and appropriate management can help control symptoms and improve quality of life for patients.

Get a Free Sample PDF Report to know more about Cutaneous T-Cell Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight

Emerging Cutaneous T-Cell Lymphoma Drugs Under Different Phases of Clinical Development Include:

• I/ONTAK: Citius Pharmaceuticals

• HyBryte: Soligenix

• Resminostat: 4SC AG

• Lacutamab: Innate Pharma

• CD11301: Galderma R&D

• Mogamulizumab: Kyowa Kirin, In

• Hypericin: oligenix

• ONTAK (denileukin difitox, DAB389IL-2): Ligand Pharmaceuticals

• Bexarotene: Bausch Health Americas, Inc.

• Forodesine 200 mg: BioCryst Pharmaceuticals

• Panobinostat: Novartis

• romidepsin (depsipeptide, FK228): Celgene

• SGX301 (synthetic hypericin): Soligenix

• Ritlecitinib: Pfizer

• BNZ132-1-40: Bioniz Therapeutics

• ONTAK: Eisai Inc.

• Pembrolizumab: Merck Sharp & Dohme LLC

Cutaneous T-Cell Lymphoma Route of Administration

Cutaneous T-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Cutaneous T-Cell Lymphoma Molecule Type

Cutaneous T-Cell Lymphoma Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Cutaneous T-Cell Lymphoma Pipeline Therapeutics Assessment

• Cutaneous T-Cell Lymphoma Assessment by Product Type

• Cutaneous T-Cell Lymphoma By Stage and Product Type

• Cutaneous T-Cell Lymphoma Assessment by Route of Administration

• Cutaneous T-Cell Lymphoma By Stage and Route of Administration

• Cutaneous T-Cell Lymphoma Assessment by Molecule Type

• Cutaneous T-Cell Lymphoma by Stage and Molecule Type

DelveInsight’s Cutaneous T-Cell Lymphoma Report covers around 35+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Cutaneous T-Cell Lymphoma product details are provided in the report. Download the Cutaneous T-Cell Lymphoma pipeline report to learn more about the emerging Cutaneous T-Cell Lymphoma therapies

Some of the key companies in the Cutaneous T-Cell Lymphoma Therapeutics Market include:

Key companies developing therapies for Cutaneous T-Cell Lymphoma are – Bausch Health Companies Inc., Celgene Corporation, Helsinn Healthcare SA, Kyowa Hakko Kirin Co. Ltd, Merck & Co. Inc., Seattle Genetics, Soligenix Inc., Equillium Inc. (Bioniz Therapeutics), miRagen Therapeutics, Innate Pharma, Citius Pharmaceuticals Inc., Bristol Myers Squibb, and others.

Cutaneous T-Cell Lymphoma Pipeline Analysis:

The Cutaneous T-Cell Lymphoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T-Cell Lymphoma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T-Cell Lymphoma Treatment.

• Cutaneous T-Cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Cutaneous T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T-Cell Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cutaneous T-Cell Lymphoma drugs and therapies

Cutaneous T-Cell Lymphoma Pipeline Market Drivers

• Increase in prevalence of Cutaneous T cell Lymphoma, growing awareness among the people regarding Cutaneous T-cell Lymphoma are some of the important factors that are fueling the Cutaneous T-Cell Lymphoma Market.

Cutaneous T-Cell Lymphoma Pipeline Market Barriers

• However, increase in prevalence of Cutaneous T cell Lymphoma, growing awareness among the people regarding Cutaneous T-cell Lymphoma and other factors are creating obstacles in the Cutaneous T-Cell Lymphoma Market growth.

Scope of Cutaneous T-Cell Lymphoma Pipeline Drug Insight

• Coverage: Global

• Key Cutaneous T-Cell Lymphoma Companies: Citius Pharmaceuticals, Soligenix, 4SC AG, Innate Pharma, Galderma R&D, Kyowa Kirin, Inc, oligenix, Ligand Pharmaceuticals, Bausch Health Americas, Inc., BioCryst Pharmaceuticals, Novartis, Celgene, Soligenix, Pfizer, Bioniz Therapeutics, Eisai Inc., Merck Sharp & Dohme LLC, and others

• Key Cutaneous T-Cell Lymphoma Therapies: I/ONTAK, HyBryte, Resminostat, Lacutamab, CD11301, Mogamulizumab, Hypericin, ONTAK (denileukin difitox, DAB389IL-2), Bexarotene, Forodesine 200 mg, Panobinostat, romidepsin (depsipeptide, FK228), SGX301 (synthetic hypericin), Ritlecitinib, BNZ132-1-40, ONTAK Pembrolizumab, and others

• Cutaneous T-Cell Lymphoma Therapeutic Assessment: Cutaneous T-Cell Lymphoma current marketed and Cutaneous T-Cell Lymphoma emerging therapies

• Cutaneous T-Cell Lymphoma Market Dynamics: Cutaneous T-Cell Lymphoma market drivers and Cutaneous T-Cell Lymphoma market barriers

Request for Sample PDF Report for Cutaneous T-Cell Lymphoma Pipeline Assessment and clinical trials

Table of Contents

1. Cutaneous T-Cell Lymphoma Report Introduction

2. Cutaneous T-Cell Lymphoma Executive Summary

3. Cutaneous T-Cell Lymphoma Overview

4. Cutaneous T-Cell Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Cutaneous T-Cell Lymphoma Pipeline Therapeutics

6. Cutaneous T-Cell Lymphoma Late Stage Products (Phase II/III)

7. Cutaneous T-Cell Lymphoma Mid Stage Products (Phase II)

8. Cutaneous T-Cell Lymphoma Early Stage Products (Phase I)

9. Cutaneous T-Cell Lymphoma Preclinical Stage Products

10. Cutaneous T-Cell Lymphoma Therapeutics Assessment

11. Cutaneous T-Cell Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cutaneous T-Cell Lymphoma Key Companies

14. Cutaneous T-Cell Lymphoma Key Products

15. Cutaneous T-Cell Lymphoma Unmet Needs

16 . Cutaneous T-Cell Lymphoma Market Drivers and Barriers

17. Cutaneous T-Cell Lymphoma Future Perspectives and Conclusion

18. Cutaneous T-Cell Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/